Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Ángela María Ruiz-Sternberg, Edson D Moreira Jr, Jaime A Restrepo, Eduardo Lazcano-Ponce, Robinson Cabello, Arnaldo Silva, Rosires Andrade, Francisco Revollo, Santos Uscanga, Alejandro Victoria, Ana María Guevara, Joaquín Luna, Manuel Plata, Claudia Nossa Dominguez, Edison Fedrizzi, Eugenio Suarez, Julio C Reina, Misoo C Ellison, Erin Moeller, Michael Ritter, Christine Shields, Miguel Cashat, Gonzalo Perez, Alain Luxembourg, Ángela María Ruiz-Sternberg, Edson D Moreira Jr, Jaime A Restrepo, Eduardo Lazcano-Ponce, Robinson Cabello, Arnaldo Silva, Rosires Andrade, Francisco Revollo, Santos Uscanga, Alejandro Victoria, Ana María Guevara, Joaquín Luna, Manuel Plata, Claudia Nossa Dominguez, Edison Fedrizzi, Eugenio Suarez, Julio C Reina, Misoo C Ellison, Erin Moeller, Michael Ritter, Christine Shields, Miguel Cashat, Gonzalo Perez, Alain Luxembourg

Abstract

Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine.

Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16-26 years, and an immunogenicity and safety study in girls and boys aged 9-15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants.

Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity.

Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden.

Trial registration: ClinicalTrials.gov NCT00543543 NCT00943722.

Keywords: 9vHPV; Cervical cancer; Human papillomavirus; Persistent infection; Vaccine.

Copyright © 2018 Merck Sharp & Dohme Corp., and The Authors. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Longitudinal anti-HPV cLIA GMTs in the per-protocol immunogenicity population by vaccination group. Vaccination visits (Day 1 and Months 2, 6, and 60) are represented by asterisks above the horizontal axis of each graph. White squares represent girls 9–15 years of age who received the 9vHPV vaccine in Study 002; black diamonds represent boys 9–15 years of age who received the 9vHPV vaccine in Study 002; black circles represent young women 16–26 years of age who received the 9vHPV vaccine in Study 001; white triangles represent young women 16–26 years of age who received the qHPV vaccine in Study 001. 9vHPV, 9-valent human papillomavirus; cLIA, competitive Luminex immunoassay; GMT, geometric mean titer; HPV, human papillomavirus; qHPV, quadrivalent human papillomavirus.

References

    1. International Agency for Research on Cancer GLOBOCAN 2012: estimated cancer incidence. Mortal. Preval. Worldw. 2012 (accessed 12 June 2017)
    1. de Martel C., Plummer M., Vignat J., Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017;141:664–670.
    1. Murillo R., Herrero R., Sierra M.S., Forman D. Cervical cancer in Central and South America: burden of disease and status of disease control. Cancer Epidemiol. 2016;44 Suppl 1:S121–S130.
    1. Vaccarella S., Lortet-Tieulent J., Plummer M. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur. J. Cancer. 2013;49:3262–3273.
    1. Bruni L., Diaz M., Barrionuevo-Rosas L. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob. Health. 2016;4:e453–e463.
    1. Pan American Health Organization (PAHO), World Health Organization (WHO), Cervical Cancer in the Americas. (accessed 11 June 2017).
    1. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–F138.
    1. Wigle J., Fontenot H.B., Zimet G.D. Global Delivery of Human Papillomavirus Vaccines. Pediatr. Clin. North Am. 2016;63:81–95.
    1. Garland S.M., Kjaer S.K., Munoz N. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin. Infect. Dis. 2016;63:519–527.
    1. Markowitz L.E., Liu G., Hariri S. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016;137:e20151968.
    1. Drolet M., Bénard É., Boily M.C. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2015;15:565–580.
    1. Technical Advisory Group on Vaccine-preventable Diseases of the Pan American Health Organization, Final Report of the XXIII Meeting of the Technical Advisory Group (TAG), 2015.
    1. de Sanjose S., Quint W.G., Alemany L. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–1056.
    1. Garland S.M., Steben M., Sings H.L. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis. 2009;199:805–814.
    1. Malagón T., Drolet M., Boily M.C. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 2012;12:781–789.
    1. Mesher D., Soldan K., Lehtinen M. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg. Infect. Dis. 2016;22:1732–1740.
    1. Tanton C., Mesher D., Beddows S. Human papillomavirus (HPV) in young women in Britain: population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017;3:36–41.
    1. Woestenberg P.J., King A.J., van der Sande M.A. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. J. Infect. 2017;74:393–400.
    1. Parkin D.M., Almonte M., Bruni L. Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine. 2008;26(Suppl 11):L1–L15.
    1. Alemany L., Saunier M., Alvarado-Cabrero I. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int. J. Cancer. 2015;136:98–107.
    1. Joura E.A., Ault A., Bosch F.X. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol. Biomark. Prev. 2014;23:1997–2008.
    1. Serrano B., de Sanjosé S., Tous S. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur. J. Cancer. 2015;51:1732–1741.
    1. Castellsague X., Ault K.A., Bosch X. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Res. 2016;2:61–69.
    1. Joura E.A., Giuliano A.R., Iversen O.E. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 2015;372:711–723.
    1. Huh W., Joura E., Giuliano A.R. Efficacy, immunogenicity, and safety of a nine-valent human papillomavirus vaccine in women aged 16–26 years: final analyses of a randomised, double-blind trial. Lancet. 2017;390:2143–2159.
    1. Van Damme P., Olsson S.E., Block S. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136:e28–e39.
    1. Chen Y.H., Gesser R., Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin. Trials. 2015;12:84–90.
    1. Luxembourg A., Bautista O., Moeller E. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp. Clin. Trials. 2015;42:18–25.
    1. Luxembourg A., Brown D., Bouchard C. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum. Vaccin. Immunother. 2015;11:1313–1322.
    1. Luxembourg A., Moreira E.D., Jr., Samakoses R. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Hum. Vaccin. Immunother. 2015;11:1306–1312.
    1. Guevara A., Cabello R., Woelber L. Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. Vaccine. 2017;35:5050–5057.
    1. World Health Organization (WHO), Guidelines to assure the quality, safety and efficacy of recombinant HPV virus-like particle vaccines. WHO/BS/06.2050, 2006.
    1. Roberts C., Green T., Hess E. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum. Vaccin. Immunother. 2014;10:2168–2174.
    1. Moreira E.D., Jr., Block S.L., Ferris D. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 Phase III clinical trials. Pediatrics. 2016;138:e20154387.
    1. Chan I.S.F., Bohidar N.R. Exact power and sample size for vaccine efficacy studies. Comm. Stat. Theory Methods. 1998;27:1305–1322.
    1. Zinkernagel R.M. On differences between immunity and immunological memory. Curr. Opin. Immunol. 2002;14:523–536.
    1. Kjaer S.K., Nygård M., Dillner J. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin. Infect. Dis. 2017;66:339–345.
    1. Luxembourg A., Kjaer S.K., Nygard M. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine. Contemp. Clin. Trials. 2017;52:54–61.
    1. Serrano B., Alemany L., Tous S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect. Agent Cancer. 2012;7:38.
    1. Lehtinen M., Apter D. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination. Curr. Opin. Obstet. Gynecol. 2015;27:326–332.
    1. Schmeler K.M., Sturgis E.M. Expanding the benefits of HPV vaccination to boys and men. Lancet. 2016;387:1798–1799.
    1. Giuliano A.R., Palefsky J.M., Goldstone S. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N. Engl. J. Med. 2011;364:401–411.
    1. Palefsky J.M., Giuliano A.R., Goldstone S. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011;365:1576–1585.
    1. Alemany L., Cubilla A., Halec G. Role of human papillomavirus in penile carcinomas worldwide. Eur. Urol. 2016;69:953–961.
    1. World Health Organization (WHO) Human papillomavirus vaccines: WHO position paper. Wkly. Epidemiol. Rec. 2017;92:241–268.
    1. World Health Organization (WHO), Guide to Introducing HPV Vaccine into National Immunization Programmes. (accessed 15 March 2017).
    1. Global Advisory Committee on Vaccine Safety, World Health Organization (WHO), Statement on Safety of HPV Vaccines. , 17 December 2015 (accessed 20 June 2017).
    1. World Health Organization (WHO) Global advisory committee on vaccine safety, 2-3 December 2015. Wkly. Epidemiol. Rec. 2016;91:21–32.
    1. World Health Organization (WHO), WHO HPV Vaccine Communication: Special considerations for a unique vaccine. (accessed 15 March 2017).

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться